• Favipiravir Pharmacokinetics in Ebola-Infected Patients of the JIKI Trial Reveals Concentrations Lower Than Targeted

      Nguyen, TH; Guedj, J; Anglaret, X; Laouénan, C; Madelain, V; Taburet, AM; Baize, S; Sissoko, D; Pastorino, B; Rodallec, A; et al. (PLoS, 2017-02-23)
      In 2014-2015, we assessed favipiravir tolerance and efficacy in patients with Ebola virus (EBOV) disease (EVD) in Guinea (JIKI trial). Because the drug had never been used before for this indication and that high concentrations of the drugs were needed to achieve antiviral efficacy against EBOV, a pharmacokinetic model had been used to propose relevant dosing regimen. Here we report the favipiravir plasma concentrations that were achieved in participants in the JIKI trial and put them in perspective with the model-based targeted concentrations.
    • An unfolding tragedy of Chagas disease in North America.

      Hotez, Peter J; Dumonteil, Eric; Betancourt Cravioto, Miguel; Bottazzi, Maria Elena; Tapia-Conyer, Roberto; Meymandi, Sheba; Karunakara, Unni; Ribeiro, Isabela; Cohen, Rachel M; Pecoul, Bernard; et al. (PLoS, 2013-11)